祥生医疗(688358) - 2024 Q1 - 季度财报

Financial Performance - The net profit attributable to shareholders of the listed company for Q1 2024 is CNY 45,539,472.75, representing a decrease of 13.28% year-on-year[15] - The net profit attributable to shareholders after deducting non-recurring gains and losses is CNY 44,879,360.93, down 13.17% compared to the same period last year[15] - The total revenue for Q1 2024 is CNY 140,596,727.46, reflecting a decline of 14.87% year-on-year[18] - The basic earnings per share for Q1 2024 is CNY 0.41, a decrease of 12.77% compared to the same period last year[15] - The weighted average return on net assets is 3.27%, a decrease of 0.57 percentage points year-on-year[15] - Total operating revenue for Q1 2024 was approximately ¥140.60 million, a decrease of 15% compared to ¥165.15 million in Q1 2023[30] - The company reported a net profit from investments of approximately ¥1.42 million in Q1 2024, down from ¥6.10 million in Q1 2023[30] - The total profit for Q1 2024 was RMB 52,411,353.09, compared to RMB 59,674,856.98 in the same period last year, a decrease of about 12.6%[42] Cash Flow and Investments - The net cash flow from operating activities is CNY 26,341,424.38, showing an increase of 698.72% compared to the previous year[15] - Cash flow from operating activities for Q1 2024 was ¥26,341,424.38, a significant improvement from ¥3,297,962.45 in Q1 2023[55] - Investment cash outflows totaled ¥890,550,070.00 in Q1 2024, up from ¥638,993,600.00 in Q1 2023, indicating a rise of approximately 39.2%[52] - The net cash generated from investment activities was ¥9,439,915.24 in Q1 2024, down from ¥35,595,811.20 in Q1 2023, indicating a decline of approximately 73%[52] - The cash inflow from investment activities was ¥904,440,201.86 in Q1 2024, compared to ¥683,471,976.07 in Q1 2023, marking an increase of approximately 32.3%[55] Assets and Liabilities - The total assets at the end of the reporting period amount to CNY 1,537,841,008.74, which is a 1.01% increase from the end of the previous year[15] - Total current assets reached RMB 1,360,337,525.55, slightly up from RMB 1,341,325,853.87 in the previous period[38] - The company reported a total liability of RMB 122,664,828.63, a decrease from RMB 153,419,489.68 in the previous period[39] - The company's total equity attributable to shareholders increased to ¥1,415,176,180.11 from ¥1,369,068,613.10, reflecting a growth of approximately 3.8% year-over-year[47] - The company's cash and cash equivalents at the end of Q1 2024 were ¥239,772,355.01, compared to ¥476,375,439.25 at the end of Q1 2023, showing a decrease of about 49.7%[52] Research and Development - The total R&D investment for the quarter is CNY 19,658,619.98, which accounts for 13.74% of operating income, an increase of 1.67 percentage points year-on-year[15] - Research and development expenses for Q1 2024 were approximately ¥19.66 million, slightly decreased from ¥19.93 million in Q1 2023[30] Expenses - Total operating costs for Q1 2024 were approximately ¥88.99 million, down from ¥111.59 million in Q1 2023, reflecting a reduction of 20.3%[30] - The company experienced a tax expense increase to approximately ¥1.11 million in Q1 2024, compared to ¥0.48 million in Q1 2023[30] - The company’s sales expenses were approximately ¥12.43 million in Q1 2024, a slight decrease from ¥13.21 million in Q1 2023[30] - The company’s management expenses increased to approximately ¥7.88 million in Q1 2024, compared to ¥6.15 million in Q1 2023[30] - Financial expenses showed a significant decrease of 214.38%, primarily due to an increase in interest income compared to the previous year[34] Government Subsidies and Other Income - The company received government subsidies amounting to CNY 730,042.46 during the quarter[12] - The total non-recurring gains and losses for the quarter amount to CNY 660,111.82 after tax[13] - The company reported a decrease in other comprehensive income, improving to -¥216,148.45 from -¥221,745.40 year-over-year[47]